多重がん検査市場-世界の産業規模、シェア、動向、競合、機会、予測、2018～2028年、検査タイプ別、技術別、サンプル別、方法別、がんタイプ別、用途別、エンドユーザー別、地域別、競合

多重がん検査市場は世界中で大きな牽引力となっています。

多重がん検査は、1つの血液サンプルから複数の種類のがんを見つける可能性があります。現在、世界で入手可能な多重がん検査には、血液検査、画像検査、遺伝子検査、リキッドバイオプシー、便検査などいくつかの種類があります。様々な種類の検査の中でも、リキッドバイオプシー検査は、迅速に実施でき、ゲノム、プロテオーム、メタボローム情報が得られ、組織生検よりも侵襲性が低いため、最も注目されています。乳がん、肺がん、大腸がん、膵臓がん、肝臓がん、卵巣がん、胃がん、食道がん、前立腺がんなどは、マルチがんスクリーニング検査によって容易に発見できるがんの種類です。世界の様々な国々、特にオーストラリア、ニュージーランド、アイルランド、ハンガリー、米国におけるがんの有病率の増加が、予測期間中に多重がん検査の需要を増加させています。また、各国で提供される医療サービスの質を向上させるために政府から提供される支援の成長も、予測期間における世界の多重がん検査市場を後押ししています。さらに、政府は毎年、新しい医療政策の実施や医療保険の導入により、各国のがん有病率を抑制するための予防対策に積極的に参加しています。さらに、国の高齢者人口の増加と、特に高齢期に人に関連する特定の種類のがんの有病率の増加も、今後数年間で世界の多重がん検査市場を押し上げると予想されます。

慢性疾患の有病率の増加

がんは世界の主要死因の1つであり、人口の高齢化、ライフスタイルの変化、環境要因などのさまざまな要因により、がんの発生率は今後数年間上昇し続けると予想されます。発展途上国の地域で最も一般的ながんの種類は乳がんです。例えば米国では、2023年に約30万590人が新たに乳がんと診断されました。乳がんに続いて世界で増加しているもう一つのがんは、肺がん、大腸がん、前立腺がん、胃がん、肝臓がん、子宮頸がんです。世界保健機関（WHO）が2022年に発表した報告書によると、2020年には世界で約226万件の乳がんが発生し、次いで肺がん221万件、結腸・直腸がん193万件、前立腺がん141万件、皮膚がん（非黒色腫）120万件、胃がん109万件となっています。世界におけるがんの有病率の増加は、年を追うごとに各国の死亡率を顕著に上昇させています。世界がん研究基金が発表した世界のがん罹患率に関する報告書によると、人口10万人当たりのがん罹患率が最も高いのはデンマークで326.1件、次いでアイルランド317件、オーストラリア314.1件、ニュージーランド309.2件、ベルギー306.8件などとなっています。複数の種類のがんの有病率の増加は、複数のがんの症状を事前に検出することができ、それによって世界の死亡率を減少させることができる多重がん検査装置の需要を増加させており、予測期間中に世界の多重がん検査市場をさらに推進すると予想されます。

政府支援の成長

多重がん検査市場とは、個人のさまざまな種類のがんを検出できる検査やサービスの開拓と販売を指します。政府の支援はこの市場の成長を促進する上で重要な役割を果たします。多くの政府が、がんスクリーニング検査や技術の研究開発に投資しています。例えば、米国の国立がん研究所は、さまざまな多重がん検査の試験や研究に資金を提供しています。また、がん検診を奨励または義務付ける政策の形成においても重要な役割を果たしています。

高齢者人口の増加

加齢に伴い、がんを発症するリスクが高まるため、国内の高齢者層におけるがん検診の需要が高まっています。全国の高齢者が通常診断される最も一般的ながんの種類には、膵臓がん、皮膚がん、膀胱がん、リンパ腫、白血病、前立腺がんなどがあります。国際がん対策連合（UICC）が2023年に発表した報告書によると、70歳以上の高齢者のうち約720万人ががんと診断され、そのうち約440万人ががんで死亡しています。しかし、高齢者のがん予防に対する意識の高まりは、予測期間中に世界の多重がん検査市場で有利な成長を記録すると予想されます。

調査範囲：

本レポートでは、世界の多重がん検査市場を以下のカテゴリーに分類し、さらに業界動向についても詳述しています。

多重がん検査市場：検査タイプ別

• 臨床検査室開発検査（LDTs）
• 体外診断薬（IVDs）

多重がん検査市場：技術別

• 次世代シーケンサー（NGS）
• ポリメラーゼ連鎖反応（PCR）
• 免疫組織化学（IHC）
• 蛍光in-situハイブリダイゼーション（FISH）
• その他の技術

多重がん検査市場：サンプル別

• 組織
• 血液
• 唾液・頬ぬぐい液
• その他

多重がん検査市場：方法別

• DNA
• RNA
• タンパク質

多重がん検査市場：がんタイプ別

• 乳がん・婦人科がん
• 消化器がん
• 内分泌がん
• 泌尿生殖器がん
• 皮膚がん
• 脳・神経系がん
• 肉腫
• 血液悪性腫瘍
• 肺がん
• 頭頸部がん
• その他

多重がん検査市場：用途別

• 臨床
• 研究

多重がん検査市場：エンドユーザー別

• 病院
• 診断および臨床研究所
• 学術研究機関
• その他のエンドユーザー

多重がん検査の世界市場：地域別

• 北米
• 米国
• カナダ
• メキシコ
• アジア太平洋
• 中国
• インド
• 韓国
• オーストラリア
• 日本
• 欧州
• ドイツ
• フランス
• 英国
• スペイン
• イタリア
• 南米
• ブラジル
• アルゼンチン
• コロンビア
• 中東＆アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

競合情勢

• 企業プロファイル：世界の多重がん検査市場に参入している主要企業の詳細分析

利用可能なカスタマイズ：

• TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です。

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の多重がん検査市場展望

• 市場規模・予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別（臨床検査室開発検査（LDTs）、体外診断薬（IVDs））
  • 技術別（次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、免疫組織化学（IHC）、蛍光in-situハイブリダイゼーション（FISH）、その他の技術）
  • サンプル別（組織、血液、唾液・頬ぬぐい液、その他）
  • 方法別（DNA、RNA、タンパク質）
  • がんタイプ別（乳がん・婦人科がん、消化器がん、内分泌がん、泌尿生殖器がん、皮膚がん、脳・神経系がん、肉腫、血液悪性腫瘍、肺がん、頭頸部がん、その他）
  • 用途別（臨床、研究）
  • エンドユーザー別（病院、診断および臨床研究所、学術研究機関、その他のエンドユーザー）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ

第6章 北米の多重がん検査市場展望

• 市場規模・予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別
  • 技術別
  • サンプル別
  • 方法別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の多重がん検査市場展望

• 市場規模・予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別
  • 技術別
  • サンプル別
  • 方法別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の多重がん検査市場展望

• 市場規模・予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別
  • 技術別
  • サンプル別
  • 方法別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の多重がん検査市場展望

• 市場規模および予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別
  • 技術別
  • サンプル別
  • 方法別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの多重がん検査市場展望

• 市場規模・予測
  • 金額・数量別
• 市場シェアと予測
  • 検査タイプ別
  • 技術別
  • サンプル別
  • 方法別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

第13章 PESTLE分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corp.
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.（GRAIL, LLC.）
• Konica Minolta, Inc.（Ambry Genetics）

第16章 戦略的提言

第17章 調査会社について・免責事項

Multi-cancer screening market is gaining significant traction across the world. Multi-cancer screening has the potential to find more than one type of cancer from a single sample of blood. Several types of multicancer screening tests that are currently accessible in the world include blood tests, imaging tests, genetic tests, liquid biopsy, stool tests, and others. Among various types of tests, the liquid biopsy test is the most prominent since it can be carried out rapidly, provides genomic, proteomic, and metabolomic information, and is less invasive than tissue biopsies. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, liver cancer, ovarian cancer, stomach cancer, esophageal cancer, and prostate cancer are some of the cancer types that can be easily detected through multi-cancer screening tests. The increasing prevalence of cancer in various countries of the world especially Australia, New Zealand, Ireland, Hungary, and the United States of America is increasing the demand for multicancer screening tests during the forecast period. Growth in the support provided by the government to improve the quality of medical services provided in every country is also propelling the global multicancer screening market in the forecast period. Moreover, the government is actively participating in taking preventive measures, for controlling the prevalence of cancer in every country by the implementation of new health policies and introduction of healthcare insurance every year. Furthermore, the growth in the geriatric population of the country and the increase in the prevalence of certain types of cancers, which are associated with people, especially during their elder age is also expected to boost the global multicancer screening market in upcoming years.

Increasing Prevalence of Chronic Diseases

Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancers, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.

Growth in Government Support

The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.

Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.

Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.

Increase in Geriatric Population

With growing age, the risk of developing cancer increases in people, which is fueling the demand for cancer screening tests among the elderly population in the country. Some of the most common types of cancers, which are usually diagnosed in elderly people across the country include pancreatic cancer, skin cancer, bladder cancer, lymphoma, leukemia, prostate cancer, and others. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer. However, growing awareness among geriatric people in passing years to prevent themselves from cancer is expected to register a lucrative growth in the global multicancer screening market during the forecast period.

Market Segmentation

The global multicancer screening market is segmented based on test type, technology, sample, method, cancer type, application, end user, and region. In terms of test type, the multicancer screening market is categorized into laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Based on technology, the global multicancer screening market is fragmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), Immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other technologies. Based on sample, the multicancer screening market is categorized into tissue, blood, saliva and buccal swab, and others. Based on this method, the market is segmented into DNA, RNA, and proteins. Based on cancer type, the global multicancer screening market is fragmented into breast and gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, hematological malignancies, lung, head and neck, and other cancer types. Based on application, the market is segmented into clinical and research. Based on end user, the market is segmented into hospitals, diagnostic and clinical laboratories, academic research institutions, and other end users.

Market Players

Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), and Konica Minolta, Inc. (Ambry Genetics).

Report Scope:

In this report, the global multicancer screening market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Multicancer Screening Market, By Test Type:

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Other Technologies

Multicancer Screening Market, By Sample:

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

Multicancer Screening Market, By Method:

• DNA
• RNA
• Proteins

Multicancer Screening Market, By Cancer Type:

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

Multicancer Screening Market, By Application:

• Clinical
• Research

Multicancer Screening Market, By End User:

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Other End Users

Global Multicancer Screening Market, By Region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the global multicancer screening market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value & Volume
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
  • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies)
  • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
  • 5.2.4. By Method (DNA, RNA, and Proteins)
  • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types)
  • 5.2.6. By Application (Clinical, Research)
  • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users)
  • 5.2.8. By Region
  • 5.2.9. By Company (2022)
• 5.3. Product Market Map

6. North America Multicancer Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value & Volume
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By Sample
  • 6.2.4. By Method
  • 6.2.5. By Cancer Type
  • 6.2.6. By Application
  • 6.2.7. By End User
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multicancer Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value & Volume
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Sample
      • 6.3.1.2.4. By Method
      • 6.3.1.2.5. By Cancer Type
      • 6.3.1.2.6. By Application
      • 6.3.1.2.7. By End User
  • 6.3.2. Mexico Multicancer Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value & Volume
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Sample
      • 6.3.2.2.4. By Method
      • 6.3.2.2.5. By Cancer Type
      • 6.3.2.2.6. By Application
      • 6.3.2.2.7. By End User
  • 6.3.3. Canada Multicancer Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value & Volume
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Sample
      • 6.3.3.2.4. By Method
      • 6.3.3.2.5. By Cancer Type
      • 6.3.3.2.6. By Application
      • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value & Volume
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By Sample
  • 7.2.4. By Method
  • 7.2.5. By Cancer Type
  • 7.2.6. By Application
  • 7.2.7. By End User
  • 7.2.8. By Country
• 7.3 Europe: Country Analysis
  • 7.3.1. France Multicancer Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value & Volume
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Sample
      • 7.3.1.2.4. By Method
      • 7.3.1.2.5. By Cancer Type
      • 7.3.1.2.6. By Application
      • 7.3.1.2.7. By End User
  • 7.3.2. Germany Multicancer Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value & Volume
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Sample
      • 7.3.2.2.4. By Method
      • 7.3.2.2.5. By Cancer Type
      • 7.3.2.2.6. By Application
      • 7.3.2.2.7. By End User
  • 7.3.3. United Kingdom Multicancer Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value & Volume
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Sample
      • 7.3.3.2.4. By Method
      • 7.3.3.2.5. By Cancer Type
      • 7.3.3.2.6. By Application
      • 7.3.3.2.7. By End User
  • 7.3.4. Italy Multicancer Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value & Volume
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Sample
      • 7.3.4.2.4. By Method
      • 7.3.4.2.5. By Cancer Type
      • 7.3.4.2.6. By Application
      • 7.3.4.2.7. By End User
  • 7.3.5. Spain Multicancer Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value & Volume
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Sample
      • 7.3.5.2.4. By Method
      • 7.3.5.2.5. By Cancer Type
      • 7.3.5.2.6. By Application
      • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value & Volume
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By Sample
  • 8.2.4. By Method
  • 8.2.5. By Cancer Type
  • 8.2.6. By Application
  • 8.2.7. By End User
  • 8.2.8. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multicancer Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value & Volume
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Sample
      • 8.3.1.2.4. By Method
      • 8.3.1.2.5. By Cancer Type
      • 8.3.1.2.6. By Application
      • 8.3.1.2.7. By End User
  • 8.3.2. India Multicancer Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value & Volume
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Sample
      • 8.3.2.2.4. By Method
      • 8.3.2.2.5. By Cancer Type
      • 8.3.2.2.6. By Application
      • 8.3.2.2.7. By End User
  • 8.3.3. South Korea Multicancer Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value & Volume
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Sample
      • 8.3.3.2.4. By Method
      • 8.3.3.2.5. By Cancer Type
      • 8.3.3.2.6. By Application
      • 8.3.3.2.7. By End User
  • 8.3.4. Japan Multicancer Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value & Volume
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Sample
      • 8.3.4.2.4. By Method
      • 8.3.4.2.5. By Cancer Type
      • 8.3.4.2.6. By Application
      • 8.3.4.2.7. By End User
  • 8.3.5. Australia Multicancer Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value & Volume
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Sample
      • 8.3.5.2.4. By Method
      • 8.3.5.2.5. By Cancer Type
      • 8.3.5.2.6. By Application
      • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value & Volume
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By Sample
  • 9.2.4. By Method
  • 9.2.5. By Cancer Type
  • 9.2.6. By Application
  • 9.2.7. By End User
  • 9.2.8. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multicancer Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value & Volume
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Sample
      • 9.3.1.2.4. By Method
      • 9.3.1.2.5. By Cancer Type
      • 9.3.1.2.6. By Application
      • 9.3.1.2.7. By End User
  • 9.3.2. Argentina Multicancer Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value & Volume
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Sample
      • 9.3.2.2.4. By Method
      • 9.3.2.2.5. By Cancer Type
      • 9.3.2.2.6. By Application
      • 9.3.2.2.7. By End User
  • 9.3.3. Colombia Multicancer Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value & Volume
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Sample
      • 9.3.3.2.4. By Method
      • 9.3.3.2.5. By Cancer Type
      • 9.3.3.2.6. By Application
      • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value & Volume
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By Sample
  • 10.2.4. By Method
  • 10.2.5. By Cancer Type
  • 10.2.6. By Application
  • 10.2.7. By End User
  • 10.2.8. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multicancer Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value & Volume
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Sample
      • 10.3.1.2.4. By Method
      • 10.3.1.2.5. By Cancer Type
      • 10.3.1.2.6. By Application
      • 10.3.1.2.7. By End User
  • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value & Volume
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Sample
      • 10.3.2.2.4. By Method
      • 10.3.2.2.5. By Cancer Type
      • 10.3.2.2.6. By Application
      • 10.3.2.2.7. By End User
  • 10.3.3. UAE Multicancer Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value & Volume
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Sample
      • 10.3.3.2.4. By Method
      • 10.3.3.2.5. By Cancer Type
      • 10.3.3.2.6. By Application
      • 10.3.3.2.7. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Agilent Technologies, Inc.
  • 15.6.2. Atara Biotherapeutics, Inc.
  • 15.6.3. Burning Rock Biotech Limited
  • 15.6.4. Exact Sciences Corp.
  • 15.6.5. F. Hoffmann-La Roche Ltd.
  • 15.6.6. Fulgent Genetics, Inc.
  • 15.6.7. Genecast Biotechnology Co., Ltd.
  • 15.6.8. Guardant Health, Inc.
  • 15.6.9. Illumina, Inc. (GRAIL, LLC.)
  • 15.6.10. Konica Minolta, Inc. (Ambry Genetics.)

16. Strategic Recommendations

17. About Us & Disclaimer